Tag: Biomedical Advanced Research and Development Authority
Vaxxas secures $2M grant from BARDA to develop needle-free mRNA vaccines
Vaxxas, a clinical-stage biotechnology company specializing in high-density microarray patch (HD-MAP) vaccine delivery, has been awarded a $2 million (AUD 3.2 million) grant as a Concept Stage winner in the United States Biomedical Advanced Research and Development Authority’s (BARDA) $50 million Patch Forward Prize.Â
Featured Article
What spending reveals about downstream consumer demand for manufactured goods
For manufacturers supplying consumer-facing markets, understanding demand conditions has become increasingly important in an environment shaped by cautious spending, rising costs and intense competition.
